Press Release

Sesen Bio to Host Conference Call to Review Fourth Quarter and Full-Year 2018 Financial Results and Additional Preliminary Data from Phase 3 VISTA Trial

February 25, 2019 at 4:20 PM EST

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 25, 2019-- Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of people with cancer, today announced that Company management will host a conference call and webcast on Monday, March 4, 2019 at 8:00 a.m. EST to review operating results for the fourth quarter and full year ended December 31, 2018 and new, preliminary analyses from the Phase 3 VISTA trial of Vicinium®for patients with high-risk non-muscle invasive bladder cancer who have been previously treated with bacillus Calmette-Guérin.

To participate in the conference call, please dial (844) 831-3025 (domestic) or (315) 625-6887 (international) and refer to conference ID 2179668. The webcast can be accessed in the Investor Relations section of the Company's website at The replay of the webcast will be available in the investor section of the Company’s website at for 60 days following the call.

About Sesen Bio
Sesen Bio, Inc. is a late-stage clinical company advancing targeted fusion protein therapeutics for the treatment of patients with cancer. The Company’s lead program, Vicinium®, also known as VB4-845, is currently in a Phase 3 registration trial, the VISTA trial, for the treatment of high-risk, BCG un-responsive non-muscle invasive bladder cancer. Updated twelve-month data from the trial are anticipated in mid-2019. Vicinium incorporates a tumor-targeting antibody fragment and a protein cytotoxic payload into a single protein molecule designed to selectively and effectively kill cancer cells, while minimizing toxicity to non-cancerous bladder cells. For more information, please visit the Company’s website at

Source: Sesen Bio, Inc.

Erin Clark, Executive Director, Strategic Planning & Investor Relations